Trial Profile
Phase I/II trial of nab-PTX/CDGP for chemo-naive patients with advanced squamous cell lung cancer (KRSG-1302)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 04 Aug 2022
Price :
$35
*
At a glance
- Drugs Nedaplatin (Primary) ; Paclitaxel (Primary)
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- 03 Aug 2022 Status changed from recruiting to completed.
- 10 Sep 2019 Updated efficacy and safety of N/nab-P in KRSG 1302 study presented at the 20th World Conference on Lung Cancer
- 17 Mar 2014 New trial record